The BIO International Convention, the world’s largest annual gathering of biotechnology stakeholders, provides an exceptional opportunity to make the connections that enable development of […]
Experts explain how to drive business development with BIO 2026 Read More »
Ohio’s diverse biotech sector provides the state with employment for 65,000 and provides the world with medical breakthroughs. Of the first eight gene therapies
BIO on the American Road tours gene therapy hub in Ohio Read More »
When a biotech firm sells investors on the promise of a new drug, what they are really selling is the intellectual property behind their
BIO is expanding its work to defend IP Read More »
As biotech celebrates its 50th year, we are locked in “the fight of our lives” to ensure patients get more of the medical innovations
Ensuring a brighter future for U.S. biotech requires modernizing the Food and Drug Administration (FDA) and addressing challenges from China, according to Kelly Seagraves,
BIO expert: Future of biotech depends on competing with China, updating FDA Read More »
A year after a congressional commission urged strategic action to prevent China from replacing America as the world leader in biotechnology, we still have
BIO CEO hails congressional report on threat of China dominating biotech Read More »
China gains a huge advantage in biotech competition by speeding up clinical trials, and America must respond, a member of the Board of the
BIO Board member advises Congress on China’s clinical trial competition Read More »
Known as “America’s Medicine Cabinet,” Puerto Rico is working to maintain its leadership in U.S. biotech production by becoming a hub for reshoring pharmaceutical
BIO on the American Road in Puerto Rico: ‘Medicine Cabinet’ ready to reshore Read More »
Proposals to let decisions by other countries control American drug prices are illegal, would reduce the availability of innovative new treatments, and fail to
BIO warns MFN models are illegal, ineffective, and a threat to innovation Read More »
Pharmacy benefit managers (PBMs) were identified as a major driver behind higher prescription drug costs in a congressional hearing that featured testimony from BIO
BIO CEO testifies in hearing highlighting PBMs’ impact on drug prices Read More »
